Raymond, Kimberly
Maher, Stephen
Saucier, Cory D.
O’Connor, Meaghan
Yarlas, Aaron
Kosinski, Mark
Chen, Wen-Hung http://orcid.org/0000-0002-6610-9709
Gairy, Kerry
Clinical trials referenced in this document:
Documents that mention this clinical trial
POS0193 EVALUATION OF CRESS IN THE PHASE 2 RANDOMISED PLACEBO-CONTROLLED STUDY OF SEQUENTIAL BELIMUMAB/RITUXIMAB ADMINISTRATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME
https://doi.org/10.1136/annrheumdis-2022-eular.1336
Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol
https://doi.org/10.1136/bmjopen-2018-025687
OP0135 SAFETY AND EFFICACY OF SUBCUTANEOUS BELIMUMAB AND INTRAVENOUS RITUXIMAB COMBINATION IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME: A PHASE 2, RANDOMISED, PLACEBO-CONTROLLED 68-WEEK STUDY
https://doi.org/10.1136/annrheumdis-2021-eular.2170
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
https://doi.org/10.1136/annrheumdis-2018-214720
Validation of the PROFAD-SSI-SF in Patients with Primary Sjögren's Syndrome with Organ Involvement: Results of Qualitative Interviews and Psychometric Analyses
https://doi.org/10.1007/s40744-022-00493-2
Funding for this research was provided by:
GSK (GSK Studies 208396, 213253)
Article History
Received: 9 June 2022
Accepted: 1 September 2022
First Online: 13 October 2022